Bupivacaine Effectiveness and Safety in SABER™ Trial (BESST)
This study has been completed.
Sponsor:
Durect
Collaborators:
Nycomed: A Takeda Company
Hospira, Inc.
Information provided by (Responsible Party):
Durect
ClinicalTrials.gov Identifier:
NCT01052012
First received: January 18, 2010
Last updated: December 20, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This is a research study testing SABER™-Bupivacaine (an experimental pain-relieving medication). SABER™-Bupivacaine is designed to continuously deliver bupivacaine, a common local anesthetic, for a few days in order to treat local post-surgical pain.
The purpose of this study is to investigate safety (side effects) associated with the use of SABER™-Bupivacaine and how well it works in reducing pain and opioid-related side effects following various kinds of abdominal surgeries.
| Condition | Intervention | Phase |
|---|---|---|
|
Postoperative Pain Abdominal Surgery |
Drug: SABER™-Bupivacaine Drug: Bupivacaine HCl Drug: SABER™-Placebo |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Bupivacaine Effectiveness and Safety in SABER™ Trial (BESST) |
Resource links provided by NLM:
Further study details as provided by Durect:
Primary Outcome Measures:
- Pain intensity on movement [ Time Frame: 0 to 3 days post-dose ] [ Designated as safety issue: No ]
- Supplemental opioid use [ Time Frame: 0 to 3 days post-dose ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Mean pain intensity on movement [ Time Frame: 0 to 2 days post-dose ] [ Designated as safety issue: No ]
- Mean total morphine-equivalent dose [ Time Frame: 0 to 2 days post-dose ] [ Designated as safety issue: No ]
- Proportion of patients who have evidence of a wound infection [ Time Frame: 0 to 14 days post-dose ] [ Designated as safety issue: No ]
- Time-to-first use of opioid rescue medication [ Time Frame: 0 to 14 days post-dose ] [ Designated as safety issue: No ]
- Incidence of opioid-related side effects [ Time Frame: 0 to 30 days post-dose ] [ Designated as safety issue: No ]
- Mean pain intensity at rest during [ Time Frame: 0 to 3 days post-dose ] [ Designated as safety issue: No ]
- Mean pain intensity at rest [ Time Frame: 0 to 2 days post-dose ] [ Designated as safety issue: No ]
- Mean scores on the Recovery Index [ Time Frame: 0 to 7 days post-dose ] [ Designated as safety issue: No ]
- Modified Post-Anesthetic Discharge Scoring System [ Time Frame: 0 to 14 days post-dose ] [ Designated as safety issue: No ]
- Treatment satisfaction [ Time Frame: 0 to 14 days post-dose ] [ Designated as safety issue: No ]
| Enrollment: | 305 |
| Study Start Date: | December 2009 |
| Study Completion Date: | September 2011 |
| Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Active: SABER™-Bupivacaine
SABER™-Bupivacaine
|
Drug: SABER™-Bupivacaine
Injectable Extended Release Solution; SABER™-Bupivacaine /Once
|
|
Active Comparator: Comparator: Bupivacaine HCl
Bupivacaine HCl
|
Drug: Bupivacaine HCl
Injectable Solution; Bupivacaine HCl /Once
|
|
Placebo Comparator: Placebo: SABER™-Placebo
SABER™-Placebo
|
Drug: SABER™-Placebo
Injectable Solution; SABER™-Placebo/Once
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients must be able to read and understand the consent form, provide written consent, complete trial-related procedures, and communicate with the trial staff
- Males and females, 18 years of age and older scheduled to undergo elective general abdominal surgery
- Patients must be healthy or have only mild systemic diseasePatients must be healthy or have only mild systemic disease
- BMI < 45
- Patients must have ECG wave form within normal limits
- Female and male patients must agree to use medically acceptable method of contraception throughout the entire trial period and for 1 week after the trial participation is completed
Exclusion Criteria:
- Patients who are pregnant or lactating
- Patients undergoing emergency surgery (unless full consent is obtained and all screening procedures are completed prior to surgery)
- Significant concomitant surgical procedure
- History of multiple prior laparotomy procedures
- Cancer with known metastases pre-operatively, which are suspected to impact post-operative recovery or pain
- Planned formation of stoma during surgery or plans to undergo another laparotomy procedure within 30 days post-operatively
- Pre-operative evidence of sepsis or septic shock
- Pre-operative evaluation that suggests a surgery may preclude full closure of the incision(s)
- Patients with current or regular use of systemic steroids, anticonvulsants, antiepileptics, antidepressants, or monoamine oxidase inhibitors, who cannot be withdrawn from these medications
- Patients with current or regular use of drugs known to significantly prolong the QTc interval
- Patients with known hypersensitivity to local anesthetic agents of the amide type (e.g. lidocaine, bupivacaine)
- Patients with known hypersensitivity to morphine
- Patients with conditions contraindicated for use of opioids
- Patients with atrial fibrillation/flutter or other non-sinus rhythm (including paced rhythm); left bundle branch block (LBBB); or the following conditions: right bundle branch block (RBBB) in presence of a cardiac disease, significant cardiomyopathy, and myocardial infarction within last 6 months
- Patients with a serum creatinine level two times more than the local laboratory normal limit
- Patients who have received greater than 600 mg morphine equivalent daily dose for three or more days per week in the month prior to the surgical procedure
- Patients who are currently being treated with methadone, or history of methadone use within the previous 6 months
- Patients with known or suspected abuse of opioids or other illicit drugs
- Patients with known or suspected alcohol abuse
- Participation in another clinical trial at the same time or within 30 days of this trial
- Patients who, in the Investigator's opinion, should not participate in the trial or may not be capable of following the trial schedule for any reason
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01052012
Show 26 Study Locations
Show 26 Study LocationsSponsors and Collaborators
Durect
Nycomed: A Takeda Company
Hospira, Inc.
Investigators
| Study Director: | Dmitri Lissin, MD | Durect Corporation |
More Information
No publications provided
| Responsible Party: | Durect |
| ClinicalTrials.gov Identifier: | NCT01052012 History of Changes |
| Other Study ID Numbers: | C803-025 |
| Study First Received: | January 18, 2010 |
| Last Updated: | December 20, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Durect:
|
Postoperative pain Post-operative pain Opioid |
Laparoscopic surgery Bupivacaine Local anesthetic |
Additional relevant MeSH terms:
|
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Signs and Symptoms Bupivacaine Anesthetics, Local Anesthetics |
Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on June 18, 2013